At present time, selective estrogen receptor downregulators (SERDs) that act as pure antagonists by interfering with the binding of estradiol to estrogen receptors (ERs) are used for hormone receptor-positive (HR+) breast cancer treatment [32]. Here, NR4A1 is linked to breast carcinoma.